Media Relations News Releases Year: - Any -20202019201820172016 Items per page 102550 Jun 1, 2018 Summary ToggleNovartis receives positive CHMP opinion for Aimovig® (erenumab) for the prevention of migraine May 17, 2018 Summary ToggleNovartis and Amgen announce FDA approval of Aimovig™ (erenumab), a novel treatment developed specifically for migraine prevention May 15, 2018 Summary ToggleNovartis successfully completes acquisition of AveXis, Inc. May 11, 2018 Summary ToggleNovartis announces FDA approval of Gilenya® as the first disease-modifying therapy for pediatric relapsing multiple sclerosis May 1, 2018 Summary ToggleKymriah® (tisagenlecleucel), first-in-class CAR-T therapy from Novartis, receives second FDA approval to treat appropriate r/r patients with large B-cell lymphoma Apr 17, 2018 Summary ToggleNovartis renews commitment to malaria elimination, investing USD 100 million to research and develop next-generation antimalarials Apr 17, 2018 Summary ToggleNovartis presents first-of-its-kind evidence at AAN reinforcing robust and consistent efficacy of AimovigTM* (erenumab) for migraine patients with multiple treatment failures Mar 22, 2018 Summary ToggleKymriah™ (tisagenlecleucel), first-in-class CAR-T therapy from Novartis, receives second FDA approval for certain adults with r/r DLBCL Feb 16, 2018 Summary ToggleNovartis new Cosentyx® data confirms robust efficacy and quality of life improvements in scalp psoriasis Feb 16, 2018 Summary ToggleNovartis new data show Cosentyx® improved quality of life over 5 years in two thirds of patients with moderate to severe plaque psoriasis Pagination First page First Previous page Previous … Page 4 Current page 5 Page 6 Page 7 … Next page Next Last page Last
